REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, September 12 Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader inthe development of microRNA-based diagnostics and therapeutics, announcedtoday the company's Chief Scientist Prof. Zvi Bentwich will present AACR'supcoming Molecular Diagnostics in Cancer Therapeutic Development conference.Prof. Bentwich's presentation will focus on Rosetta Genomics uniquemicroRNA-based technologies and current development programs. The event willtake place at the Atlanta Hilton, Atlanta.
The presentation, titled, "Human microRNAs: Powerful Biomarkers forCancer Diagnostics", is part of a plenary session on the molecularclassification of tumors, which will be held on Wednesday, September 19,between 10:45 am-1:00 pm.
An audio webcast of the presentation will be made available by AACR 15days after the conference at the following url:http://www.aacr.org/home/scientists/meetings--workshops/molecular-diagnostics-in-cancer-therapeutic-development.aspx
(Due to the length of this URL, it may be necessary to copy and pastethis hyperlink into your Internet browser's URL address field. Remove thespace if one exists.)
About Rosetta Genomics
Rosetta Genomics (Nasdaq:ROSG) is a leader in the development ofmicroRNA-based diagnostics and therapeutics. Founded in 2000, the company'sintegrative research platform combining bioinformatics and state-of-the-artlaboratory processes has led to the discovery of hundreds of biologicallyvalidated novel human microRNAs. Building on its strong IP position andstrategic alliances with leading biotechnology companies, Rosetta Genomics isworking to develop a full range of diagnostic and therapeutic products basedon microRNAs. The company's primary focus is in the development ofmicroRNA-based products to diagnose and treat different forms of cancer andvarious diseases. For more information please visit:http://www.rosettagenomics.comContact: Media Alan Zachary T: +1-312-944-6784 firstname.lastname@example.org Investors Juliane Snowden T: +1-212-213-0006 email@example.com
SOURCE Rosetta Genomics Ltd